◆英語タイトル:Teijin Pharma Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013394
◆発行会社(調査会社):
GlobalData
◆発行日:2017年11月28日
◆ページ数:31
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:日本
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
Teijin Pharma Ltd (Teijin Pharma), a subsidiary of Teijin Ltd develops, manufactures and markets pharmaceutical and home healthcare products. The company offers a range of pharmaceutical products for the treatment of bone and joint diseases, respiratory diseases and cardiovascular and metabolic diseases. Its pharmaceutical products comprise inhaled corticosteroid for asthma, osteoporosis drugs, anti-hyperuricemia agent, and others. Its pharmaceutical pipeline products are intended for the treatment of tumor lysis syndrome, adenosine deaminase deficiency, optic neuritis, microscopic polyangiitis, neuroendocrine tumor, lumbar disc herniation, type 2 diabetes and others. Teijin Pharma’s home healthcare equipments include oxygen concentrators, sonic accelerated fracture healing system, and continuous positive airway pressure devices. The company has a presence in Europe, Asia and North America. Teijin Pharma is headquartered in Tokyo, Japan.
Teijin Pharma Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Teijin Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Teijin Pharma Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Teijin Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Teijin Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Teijin Pharma Ltd, Medical Devices Deals, 2011 to YTD 2017 9
Teijin Pharma Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Teijin Pharma Ltd, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Teijin Pharma Enters into Discovery Agreement with PeptiDream 11
Teijin Pharma And Amgen Enter Into R&D Agreement To Develop Autoimmune Disease Therapies 12
Teijin Pharma Extends Co-Marketing Agreement With Menarini For TMX-67 13
NovAliX Enters Into Multi-Target Integrated Drug Discovery Collaboration With Teijin Pharma 14
Teijin Pharma Enters Into Distribution Agreement With Astellas Pharma For Febuxostat 15
Teijin Pharma Enters Into Co-Marketing Agreement With Takeda Pharma North America For TMX-67 16
Teijin Pharma Enters Into Co-Marketing Agreement With Algorithm For TMX-67 17
Teijin Pharma Enters Into Co-Marketing Agreement With Menarini Group For TMX-67 18
Licensing Agreements 19
Merck Enters into Licensing Agreement with Teijin Pharma 19
Amgen Enters into Licensing Agreement with Teijin Pharma 20
Teijin Pharma Enters into Licensing Agreement with Versartis 21
Teijin Pharma Enters Into Licensing Agreement With Pulmagen Therapeutics For ADC3680 22
Teijin Pharma Ltd – Key Competitors 23
Teijin Pharma Ltd – Key Employees 24
Teijin Pharma Ltd – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Joint Venture 26
Recent Developments 27
Corporate Communications 27
Feb 06, 2017: Teijin Board Elects Akihisa Nabeshima as New President of Teijin Pharma 27
Product News 28
05/23/2016: Teijin Pharma’s Feburic (Febuxostat) Approved as Indication for Cancer Chemotherapy-Induced Hyperuricemia 28
Product Approvals 29
Jun 15, 2016: Scottish Medicines Consortium Accepts Adenuric (Febuxostat) for the Prevention and Treatment of Hyperuricaemia and Predicts Savings for NHS Scotland 29
Clinical Trials 30
Nov 13, 2016: Results of Study of Febuxostat on the Frequency of Acute Gout Flares in Early Gout 30
Appendix 31
Methodology 31
About GlobalData 31
Contact Us 31
Disclaimer 31
List of Tables
Teijin Pharma Ltd, Pharmaceuticals & Healthcare, Key Facts 2
Teijin Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Teijin Pharma Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Teijin Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Teijin Pharma Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
Teijin Pharma Ltd, Medical Devices Deals, 2011 to YTD 2017 9
Teijin Pharma Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Teijin Pharma Enters into Discovery Agreement with PeptiDream 11
Teijin Pharma And Amgen Enter Into R&D Agreement To Develop Autoimmune Disease Therapies 12
Teijin Pharma Extends Co-Marketing Agreement With Menarini For TMX-67 13
NovAliX Enters Into Multi-Target Integrated Drug Discovery Collaboration With Teijin Pharma 14
Teijin Pharma Enters Into Distribution Agreement With Astellas Pharma For Febuxostat 15
Teijin Pharma Enters Into Co-Marketing Agreement With Takeda Pharma North America For TMX-67 16
Teijin Pharma Enters Into Co-Marketing Agreement With Algorithm For TMX-67 17
Teijin Pharma Enters Into Co-Marketing Agreement With Menarini Group For TMX-67 18
Merck Enters into Licensing Agreement with Teijin Pharma 19
Amgen Enters into Licensing Agreement with Teijin Pharma 20
Teijin Pharma Enters into Licensing Agreement with Versartis 21
Teijin Pharma Enters Into Licensing Agreement With Pulmagen Therapeutics For ADC3680 22
Teijin Pharma Ltd, Key Competitors 23
Teijin Pharma Ltd, Key Employees 24
Teijin Pharma Ltd, Other Locations 25
Teijin Pharma Ltd, Subsidiaries 25
Teijin Pharma Ltd, Joint Venture 26